Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sustained release 4-aminopyridine (Fampyra) in cerebellar gait disorder

Trial Profile

Sustained release 4-aminopyridine (Fampyra) in cerebellar gait disorder

Phase of Trial: Phase III

Latest Information Update: 13 Nov 2018

At a glance

  • Drugs Fampridine (Primary)
  • Indications Cerebellar ataxia; Gait disturbances
  • Focus Therapeutic Use
  • Acronyms FACEG
  • Most Recent Events

    • 07 Dec 2016 Status changed from recruiting to completed.
    • 11 Dec 2013 New source identified and integrated (German Clinical Trials Register, DRKS00004783).
    • 28 Mar 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top